Navigation Links
Newly Published Menopause Study: 'Bioidentical' and FDA-Approved Divigel(R) (estradiol gel) 0.1 Percent Safe and Effective Treatment for Moderate to Severe Hot Flashes Associated With Menopause
Date:2/17/2009

MAPLE GROVE, Minn., Feb. 17 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. announced today the publication of results of a Phase III study demonstrating that Divigel(R) low-dose transdermal estradiol gel 0.1% is an effective treatment for relief of moderate to severe hot flashes associated with menopause. The objective of the study was to evaluate the efficacy and safety of three doses of Divigel(R) 0.1%, 1.0 mg, 0.5 mg, and, 0.25 mg/day, including the lowest approved dose of estradiol gel or lotion available for the treatment of vasomotor symptoms (1-4). Data showed a statistically significant reduction in frequency and severity of hot flashes as early as week two in patients receiving Divigel(R). The results were published in the January/February edition of Menopause: Journal of the North American Menopause Society (NAMS).

About the Study

A total of 488 postmenopausal women were evaluated in a 12-week study comparing placebo with estradiol gel 0.1% at doses of 1.0, 0.5, and 0.25 mg/day, with estimated daily deliveries of 0.027, 0.009, and 0.003 mg of estradiol, respectively. Primary endpoints were the change from baseline in daily frequency and severity of moderate to severe vasomotor symptoms. Change from baseline in the signs of vulvar and vaginal atrophy (vaginal pH and percentage of superficial cells) was also assessed. Treatment with estradiol gel 0.1% showed statistically significant reductions in frequency and severity of vasomotor symptoms from baseline compared with placebo, as early as Week 2, that were maintained throughout treatment. Signs of vulvar and vaginal atrophy were also significantly improved from baseline with all three doses of estradiol gel 0.1% compared with placebo.

"The development of Divigel(R) expands the bioidentical options for the effective treatment of the symptoms of menopause and offers women the lowest FDA-approved dose of estrogen therapy for hot flashes," Dr. Richard Hedrick, Jr., key investigator, Hawthorne OB/GYN Associates. "Divigel(R) also offers dosing flexibility with availability of three different strengths (0.25 mg estradiol/day, 0.5 mg estradiol/day and 1.0 mg estradiol/day) giving physicians greater ability to individualize treatment for each woman."

About Divigel(R)

Divigel(R) is indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause. The estrogen in Divigel(R) is derived from plant sources and is identical to the primary estrogen produced by a woman's ovaries before menopause. Certain older oral estrogen therapies contain conjugated estrogens derived from the urine of pregnant mares. Divigel(R) is a quick-drying gel that is odorless when dry, and is available in convenient, individual-use packets. One packet of gel is applied daily to an area that measures approximately 5 x 7 inches on the thigh, the smallest application area compared to all other available gel or lotion estrogen products (1-4). After the gel is applied, it absorbs directly into the bloodstream without having to pass through the liver.

Divigel(R) was approved by the U.S. Food and Drug Administration (FDA) in June 2007.

Important Safety Information for Patients

The following are not all the possible risks for Divigel(R). Please read the full Patient Information leaflet and talk to your healthcare provider.

Estrogens increase the chance of getting cancer of the uterus. Report any unusual vaginal bleeding right away while you are taking estrogens. Vaginal bleeding after menopause may be a warning sign of cancer of the uterus (womb). Your healthcare provider should check any unusual vaginal bleeding to find out the cause. In general, the addition of a progestin is recommended for women with a uterus to reduce the chance of getting cancer of the uterus.

Do not use estrogens, with or without progestins, to prevent heart disease, heart attacks, or strokes. Using estrogens, with or without progestins, may increase your chance of getting heart attacks, strokes, breast cancer, and blood clots.

Do not use estrogens, with or without progestins, to prevent dementia. Using estrogens, with or without progestins, may increase your risk of dementia.

Do not use estrogen products, including Divigel(R), if you have unusual vaginal bleeding, currently have or have had certain cancers, had a stroke or heart attack in the past year, currently have or have had blood clots, currently have or have had liver problems, are allergic to any Divigel(R) ingredients, or think you may be pregnant.

The most common side effects for all estrogen products are headache, breast pain, irregular vaginal bleeding or spotting, stomach/abdominal cramps and bloating, nausea and vomiting, and hair loss. Less common but serious side effects include breast cancer, cancer of the uterus, stroke, heart attack, blood clots, dementia, gallbladder disease and ovarian cancer.

In Divigel(R) clinical trials, the most common side effects were inflammation of the nasal passages and pharynx, upper respiratory tract infection, vaginal yeast infection, breast tenderness and vaginal bleeding. Call your healthcare provider right away if you have any symptoms that concern you.

Estrogen products should be used at the lowest dose possible for your treatment and only as long as needed. You and your healthcare provider should talk regularly about whether you still need treatment with Divigel(R).

For more information, call 1-800-654-2299 or visit http://www.divigel.com.

Orion Corporation (OMX: ORNAV, ORNBV) has a licensing agreement with Upsher-Smith Laboratories for the development of Divigel(R) in the United States. Orion is one of the leading pharmaceutical companies in northern Europe through its development, manufacturing and marketing of pharmaceuticals, active pharmaceutical ingredients and diagnostic tests for global markets. The core therapeutic areas in Orion's product and research strategy are central nervous system disorders, cardiology, critical care and hormonal and urological therapies.

Upsher-Smith Laboratories, Inc. is a rapidly growing pharmaceutical company that manufactures and markets both prescription and consumer products. Privately held since 1919, the company strives to recognize the unmet healthcare needs of our customers. Upsher-Smith prides itself in providing safe, effective, and economical therapies to the ever-challenged healthcare environment. For additional information about Upsher-Smith, visit http://www.upsher-smith.com.

References: 1. Divigel(R) [package insert]. Minneapolis, MN: Upsher-Smith Laboratories, Inc.; 2007. 2. Estrasorb(R) [package insert]. Bristol, TN: Graceway Pharmaceuticals, LLC; 2008. 3. EstroGel(R) [package insert]. Herndon, VA: Ascend Therapeutics, Inc.; 2007. 4. Elestrin(TM) [package insert]. Lincolnshire, IL: BioSante Pharmaceuticals, Inc.; 2007.


'/>"/>
SOURCE Upsher-Smith Laboratories, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. RADinfo SYSTEMS(TM) is Pleased to Introduce Their Newly Established Division, VETinfo SYSTEMS(TM)
2. New Diabetes Resource Provides Tools and Support to Families of Newly-Diagnosed Children with Type 1 Diabetes
3. Newly Described Contaminant Sources in Katrina-Flooded Homes Pose Health Risks
4. A Newly Approved CMS Medicare Package Expands Reimbursement Coverage for Telehealth Originating Sites Beginning January 1, 2009
5. Newly Released Book by Retired Scientist Links Self-Control of Hormones to Perfecting One's Life
6. Seattle Reproductive Medicine Study Investigates Newly Formulated Medications for Luteal Support in IVF
7. Newly Reactivated Health Economics Research Institute to Launch New Initiatives for Improving Health Care Delivery
8. Go Ask Alice ... Nationally Recognized Life Coach & Psychotherapist, Alice Donavin, LCSW Announces the Implementation of Office/House Calls to her Newly Launched Philadelphia Practice
9. Newly discovered esophagus stem cells grow into transplantable tissue, Penn study finds
10. Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkins Lymphoma
11. New Requirements of EU Medical Device Directive Need Immediate Action, Nerac Analysts Urge in Newly Published White Paper
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... January 24, 2017 , ... ... semi-final round of the 2017 Cupid's Cup Entrepreneurship Competition. Chaired by Under Armour ... in 2017. The entrepreneurs will showcase their businesses on February 6, 2017, at ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... today that its annual Solutions Series of webinars will start January 31 with ... discussing a number of current health and benefits topics, including employee engagement, pricing ...
(Date:1/24/2017)... ... January 24, 2017 , ... His message has been heard by more than ... End Distracted Driving , Joel Feldman, has reached his biggest national audience yet: the ... of the top newspapers in circulation in the country, and he hopes it will ...
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... Center ... 21st century leadership, has named Hector M. Chavez, Manager, Employee & Labor Relations at ... center - as its Hispanic Leader of the Month. City of Hope is committed ...
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... ... is the focus of a new report from the Frank Hawkins Kenan ... School. , Influential business leaders, academics and policy makers identified concrete solutions at ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... Aptuit, LLC, hat heute den ... Massachusetts General Hospital (MGH) unter Leitung von Dr. ... Identifizierung und Validierung neuartiger Targets in gramnegativen Bakterien.  Aptuit ... von Antibiotika bei der Behandlung schwerer Infektionen entgegenwirken können. ... ...
(Date:1/24/2017)... -- Laboratory Markets Limited has completed a comprehensive market ... both clinical and research laboratory settings. This study, which ... $6.8 billion and growing to $9.2 billion (CAGR of ... of mass spectrometry across more than 5,200 clinical and ... in the use of mass spectrometry in terms of ...
(Date:1/24/2017)... 2017 Global Market for Pharmaceutical ... A majority of medicines & drugs produced in ... (API), and such processes require alcoholic solvents such as ... of pharmaceutical solvents continues to be concentrated in the ... (APEJ) region as leading API suppliers and ...
Breaking Medicine Technology: